Evidence map›Paper›PMID 21518455›Full record

ArticleReproductive biology and endocrinology : RB&E2011

Peripheral myelin protein-22 (PMP22) modulates alpha 6 integrin expression in the human endometrium.

Rajiv G Rao, Deepthi Sudhakar, Claire P Hogue, Stephanie Amici, Lynn K Gordon, Jonathan Braun, Lucia Notterpek, Lee Goodglick, Madhuri Wadehra

Open access · goldAbstract read
In one paragraph

Article in Reproductive biology and endocrinology : RB&E, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. miR-200bc/429 Inhibits Osteosarcoma Cell Proliferation and Invasion by Targeting PMP22.Medical science monitor : international medical journal of experimental and clinical research · 2017
    Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Rajiv G RaoDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, USA.
Deepthi Sudhakar
Claire P Hogue
Stephanie Amici
Lynn K Gordon
Jonathan Braun
Lucia Notterpek
Lee Goodglick
Madhuri Wadehra
University of California, Los Angeles · USUniversity of Florida · US

Funding

Vision Research Core at UCLAP30EY000331 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Gregory Darin Field, DAVID S WILLIAMS · 1985 to 2026
$16.8M
The Early Detection Research Network Biomarker Resource Laboratory at UCLAU24CA086366 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHIA, DAVID S. · 2000 to 2014
$7.3M
Targeting EMP2 in Endometrial CancerR21CA131756 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WADEHRA, MADHURI · 2009 to 2010
$373k
Abnormal EMPS Expression Affects Pregnancy OutcomeR03HD048540 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BRAUN, JONATHAN · 2005 to 2006
$305k
NCI NIH HHS CA131756NCI NIH HHS CA86366NEI NIH HHS P30 EY000331NICHD NIH HHS HD48540
6 · The paper itself

Abstract

backgroundPMP22, a member of the GAS3 family of tetraspan proteins, is associated with a variety of neurological diseases. Previous studies have shown that PMP22 is expressed in proliferative endometrium, but its function within this tissue is poorly understood. In this study, we first characterized the expression of PMP22 in the human menstrual cycle and began to characterize its function in the endometrium.

methodsUsing a combination of immunohistochemistry and quantitative PCR, we characterized the expression of PMP22 in both proliferative and secretory endometrium. Differences in PMP22 expression between proliferative and secretory endometrium were determined using a Mann-Whitney U test. In order to investigate the influence of PMP22 on α6 integrin expression, cells were created that ectopically overexpressed PMP22 or expressed a siRNA to inhibit its expression. These cells were analyzed for changes in integrins and binding to extracellular matrices.

resultsIn this study, we show that PMP22 expression is higher in proliferative phase than secretory phase. Functionally, we have begun to characterize the functional significance of this expression. Previous studies have suggested a link between PMP22 and α6 integrin, and therefore we asked whether PMP22 could associate or potentially modulate the expression of α6 integrin. Expression of both PMP22 and α6 integrin were detectable in endometrial epithelial and stromal cells, and we show that both proteins can associate and colocalize with each other. To understand if PMP22 directly altered the expression of a6 integrin, we examined cell lines with modulated levels of the protein. Overexpression of PMP22 was sufficient to increase α6 integrin surface expression with a concominant increase in binding to the extracellular matrix laminin, while a reduction in PMP22 suppressed α6 integrin surface expression.

conclusionThese findings suggest a physiologic role for PMP22 on the expression of α6 integrin. We predict that this may be important for the maintainence of endometrial integrity and to the disease biology associated with altered levels of α6 integrin expression in the endometrium.

Indexed as

Cell AdhesionCell Line, TumorEndometriumFemaleGene Expression RegulationHumansImmunoprecipitationIntegrin alpha6Menstrual CycleMyelin ProteinsProtein BindingRetrospective StudiesTissue DistributionValidation Studies as TopicIntegrin alpha6Myelin ProteinsPMP22 protein, human

Identifiers

PMID21518455
PMCPMC3110552
OpenAlexW2136824984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.